Carlos Manuel González-Casimiro

Dr. Carlos Manuel González-Casimiro

Instituto de Biología y Genética Molecular, Valladolid, Castille-Leon, Spain
orcid
MD, PhD, Postdoctoral Researcher

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
Carlos Manuel González-CasimiroCarlos Manuel González-Casimiro
Carlos Manuel González-Casimiro
Beatriz MerinoBeatriz Merino
Beatriz Merino
ECElena Casanueva-Álvarez
Elena Casanueva-Álvarez
TPTamara Postigo-Casado
Tamara Postigo-Casado
PCPatricia Cámara-Torres
Patricia Cámara-Torres
German PerdomoGerman Perdomo
German Perdomo
Insulin-degrading enzyme (IDE) is a highly conserved and ubiquitously expressed metalloprotease that degrades insulin and several other intermediate-size peptides. For many decades, IDE had been assumed to be involved primarily in hepatic insulin clearance, a key process that regulates availability of circulating insulin levels for peripheral tissues. Emerging evidence, however, suggests that IDE has several other important physiological functions relevant to glucose and insulin homeostasis, including the regulation of insulin secretion from pancreatic β-cells. Investigation of mice with tissue-specific genetic deletion of Ide in the liver and pancreatic β-cells (L-IDE-KO and B-IDE-KO mice, respectively) has revealed additional roles for IDE in the regulation of hepatic insulin action and sensitivity. In this review, we discuss current knowledge about IDE’s function as a regulator of insulin secretion and hepatic insulin sensitivity, both evaluating the classical view of IDE as an insulin protease and also exploring evidence for several non-proteolytic functions. Insulin proteostasis and insulin sensitivity have both been highlighted as targets controlling blood sugar levels in type 2 diabetes, so a clearer understanding the physiological functions of IDE in pancreas and liver could led to the development of novel therapeutics for the treatment of this disease.

Verified
Journal Article
Open access
PDF file
Malcolm LeissringMalcolm Leissring
Malcolm Leissring
Carlos Manuel González-CasimiroCarlos Manuel González-Casimiro
Carlos Manuel González-Casimiro
Beatriz MerinoBeatriz Merino
Beatriz Merino
CSCaitlin Suire
Caitlin Suire
German PerdomoGerman Perdomo
German Perdomo
Hepatic insulin clearance, a physiological process that in response to nutritional cues clears ~50–80% of circulating insulin, is emerging as an important factor in our understanding of the pathogenesis of type 2 diabetes mellitus (T2DM). Insulin-degrading enzyme (IDE) is a highly conserved Zn2+-metalloprotease that degrades insulin and several other intermediate-size peptides. Both, insulin clearance and IDE activity are reduced in diabetic patients, albeit the cause-effect relationship in humans remains unproven. Because historically IDE has been proposed as the main enzyme involved in insulin degradation, efforts in the development of IDE inhibitors as therapeutics in diabetic patients has attracted attention during the last decades. In this review, we retrace the path from Mirsky’s seminal discovery of IDE to the present, highlighting the pros and cons of the development of IDE inhibitors as a pharmacological approach to treating diabetic patients.

9 September 2020 in Metabolism
Verified
Journal Article
Open access
BMBeatriz Merino
Beatriz Merino
CFCristina M. Fernández-Díaz
Cristina M. Fernández-Díaz
CFCristina Fernández-Díaz
Cristina Fernández-Díaz
Carlos Manuel González-CasimiroCarlos Manuel González-Casimiro
Carlos Manuel González-Casimiro
TPTamara Postigo-Casado
Tamara Postigo-Casado
German PerdomoGerman Perdomo
German Perdomo
These studies were undertaken to further investigate its regulatory role in glucose homeostasis and insulin sensitivity in diet-induced obesity. To this end, we have compared the metabolic effects of loss versus gain of IDE function in mice fed a high-fat diet (HFD). We demonstrate that loss of IDE function in liver (L-IDE-KO mouse) exacerbates hyperinsulinemia and insulin resistance without changes in insulin clearance but in parallel to an increase in pancreatic β-cell function. Insulin resistance was associated with increased FoxO1 activation and a ~2-fold increase of GLUT2 protein levels in the liver of HFD-fed mice in response to an intraperitoneal injection of insulin. Conversely, gain of IDE function (adenoviral delivery) improves glucose tolerance and insulin sensitivity, in parallel to a reciprocal ~2-fold reduction in hepatic GLUT2 protein levels. Furthermore, in response to insulin, IDE co-immunoprecipitates with the insulin receptor in liver lysates of mice with adenoviral-mediated liver overexpression of IDE. We conclude that IDE regulates hepatic insulin action and whole-body glucose metabolism in diet-induced obesity via insulin receptor levels.

2 June 2022 in Diabetologia
Verified
Journal Article
Open access
PDF file
Beatriz MerinoBeatriz Merino
Beatriz Merino
ECElena Casanueva-Alvarez
Elena Casanueva-Alvarez
IQIvan Quesada
Ivan Quesada
Carlos Manuel González-CasimiroCarlos Manuel González-Casimiro
Carlos Manuel González-Casimiro
CFCristina Fernández-Díaz
Cristina Fernández-Díaz
ICIrene Cozar-Castellano
Irene Cozar-Castellano
Aims/hypothesis: Type 2 diabetes is characterised by hyperglucagonaemia and perturbed function of pancreatic glucagon-secreting alpha cells but the molecular mechanisms contributing to these phenotypes are poorly understood. Insulin-degrading enzyme (IDE) is present within all islet cells, mostly in alpha cells, in both mice and humans. Furthermore, IDE can degrade glucagon as well as insulin, suggesting that IDE may play an important role in alpha cell function in vivo. Methods: We have generated and characterised a novel mouse model with alpha cell-specific deletion of Ide, the A-IDE-KO mouse line. Glucose metabolism and glucagon secretion in vivo was characterised; isolated islets were tested for glucagon and insulin secretion; alpha cell mass, alpha cell proliferation and α-synuclein levels were determined in pancreas sections by immunostaining. Results: Targeted deletion of Ide exclusively in alpha cells triggers hyperglucagonaemia and alpha cell hyperplasia, resulting in elevated constitutive glucagon secretion. The hyperglucagonaemia is attributable in part to dysregulation of glucagon secretion, specifically an impaired ability of IDE-deficient alpha cells to suppress glucagon release in the presence of high glucose or insulin. IDE deficiency also leads to α-synuclein aggregation in alpha cells, which may contribute to impaired glucagon secretion via cytoskeletal dysfunction. We showed further that IDE deficiency triggers impairments in cilia formation, inducing alpha cell hyperplasia and possibly also contributing to dysregulated glucagon secretion and hyperglucagonaemia. Conclusions/interpretation: We propose that loss of IDE function in alpha cells contributes to hyperglucagonaemia in type 2 diabetes.

16 September 2021 in Cells
Verified
Journal Article
Open access
PDF file
Carlos Manuel González-CasimiroCarlos Manuel González-Casimiro
Carlos Manuel González-Casimiro
PCPatricia Cámara-Torres
Patricia Cámara-Torres
Beatriz MerinoBeatriz Merino
Beatriz Merino
SDSergio Diez-Hermano
Sergio Diez-Hermano
TPTamara Postigo-Casado
Tamara Postigo-Casado
German PerdomoGerman Perdomo
German Perdomo
Insulin-degrading enzyme (IDE) is a highly conserved and ubiquitously expressed Zn2+-metallopeptidase that regulates hepatic insulin sensitivity, albeit its regulation in response to the fasting-to-postprandial transition is poorly understood. In this work, we studied the regulation of IDE mRNA and protein levels as well as its proteolytic activity in the liver, skeletal muscle, and kidneys under fasting (18 h) and refeeding (30 min and 3 h) conditions, in mice fed a standard (SD) or high-fat (HFD) diets. In the liver of mice fed an HFD, fasting reduced IDE protein levels (~30%); whereas refeeding increased its activity (~45%) in both mice fed an SD and HFD. Likewise, IDE protein levels were reduced in the skeletal muscle (~30%) of mice fed an HFD during the fasting state. Circulating lactate concentrations directly correlated with hepatic IDE activity and protein levels. Of note, L-lactate in liver lysates augmented IDE activity in a dose-dependent manner. Additionally, IDE protein levels in liver and muscle tissues, but not its activity, inversely correlated (R2 = 0.3734 and 0.2951, respectively; p < 0.01) with a surrogate marker of insulin resistance (HOMA index). Finally, a multivariate analysis suggests that circulating insulin, glucose, non-esterified fatty acids, and lactate levels might be important in regulating IDE in liver and muscle tissues. Our results highlight that the nutritional regulation of IDE in liver and skeletal muscle is more complex than previously expected in mice, and that fasting/refeeding does not strongly influence the regulation of renal IDE.

27 June 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
MPMarta Pablos
Marta Pablos
ECElena Casanueva-Álvarez
Elena Casanueva-Álvarez
Carlos Manuel González-CasimiroCarlos Manuel González-Casimiro
Carlos Manuel González-Casimiro
BMBeatriz Merino
Beatriz Merino
GPGermán Perdomo
Germán Perdomo
ICIrene Cózar-Castellano
Irene Cózar-Castellano
The primary cilium is a narrow organelle located at the surface of the cell in contact with the extracellular environment. Once underappreciated, now is thought to efficiently sense external environmental cues and mediate cell-to-cell communication, because many receptors, ion channels, and signaling molecules are highly or differentially expressed in primary cilium. Rare genetic disorders that affect cilia integrity and function, such as Bardet-Biedl syndrome and Alström syndrome, have awoken interest in studying the biology of cilium. In this review, we discuss recent evidence suggesting emerging roles of primary cilium and cilia-mediated signaling pathways in the regulation of pancreatic β- and α-cell functions, and its implications in regulating glucose homeostasis.